No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study
Abstract
The long-term use of the serotonin-releaser and uptake-inhibitor 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) has been associated with memory impairments and increased liability to depressive mood and anxiety attacks. It is unclear, however, whether these psychologic deviations are reflected in alterations of the underlying neurophysiologic substrate. The authors compared mood and regional cerebral blood flow (rCBF) profiles between regular polytoxic Ecstasy users and Ecstasy-naive controls. Brain activity as indexed by rCBF was measured during cognitive activation by an attentional task using positron emission tomography and [fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][H2(15)O]. Mood was assessed by means of the Hamilton Rating Scale for Depression (HAM-D) and the EWL Mood Rating Scale. Statistical parametric mapping revealed that brain activity did not differ between the two groups. Both groups also performed equally on the cognitive task requiring sustained attention. However, significantly higher levels of depressiveness as determined by the HAM-D and EWL scales were found in Ecstasy-using subjects. These data indicate that, despite differences in mood, polytoxic Ecstasy users do not differ from Ecstasy-naive controls in terms of local brain activity. Heightened depressiveness in the Ecstasy group was consistent with results from previous studies and could be related to serotonergic hypofunction resulting from repeated MDMA consumption. However, this study cannot exclude the possibility that the observed differences are preexisting rather than a result of Ecstasy use.
Gamma, A., Buck, A., Berthold, T., & Vollenweider, F. X. (2001). No difference in brain activation during cognitive performance between ecstasy (3, 4-methylenedioxymethamphetamine) users and control subjects: a [H215O]-positron emission tomography study. Journal of clinical psychopharmacology, 21(1), 66-71. http://dx.doi.org/10.1097/00004714-200102000-00012
[/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]
The sensationalism surrounding the widespread use of LSD in the late 60s and the subsequent legislative overkill virtually ended psychotherapeutic LSD research. Much of what had been learned over thirty years of scientific medical study was so distorted or suppressed that no objective overview was available to the general reader – except for this book. LSD Psychotherapy is a complete account of a remarkable chapter in the ever-continuing inquiry into our transpersonal nature and origins. The controlled studies described in this book reveal exciting and challenging data about the nature of human consciousness, perception, and reality itself. Drawing on this work Dr. Stanislav Grof outlines a new cartography of the human mind, one which accounts for experiences such as shamanic trance, near-death experiences and altered states of consciousness. This vision is also the foundation for Dr. Grof’s revolutionary new Holotropic Breathwork™ techniques. This book is also a visual feast, with numerous color drawings and paintings created by research participants (see featured artist Sherana Harriette Frances’ book Drawing It Out: Befriending the Unconscious). Many of these depict archetypal images from the collective human consciousness, which form a powerful addition to the text. LSD Psychotherapy is a valuable source of information for those who are involved with LSD in any way, as parents, teachers, researchers, legislators, or students of the human psyche. The approach to healing described in this book is inspired by the eternal desire of humankind for wholeness and an enduring grasp of reality.
From 1990 to 1995 Dr. Rick Strassman conducted U.S. Government-approved and funded clinical research at the University of New Mexico in which he injected sixty volunteers with DMT, one of the most powerful psychedelics known. His detailed account of those sessions is an extraordinarily riveting inquiry into the nature of the human mind and the therapeutic potential of psychedelics. DMT, a plant-derived chemical found in the psychedelic Amazon brew, ayahuasca, is also manufactured by the human brain. In Strassman’s volunteers, it consistently produced near-death and mystical experiences. Many reported convincing encounters with intelligent nonhuman presences, aliens, angels, and spirits. Nearly all felt that the sessions were among the most profound experiences of their lives.